Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
US8394796B2 · kind B2 · utility
7Cited by
16References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 22, 2012 |
| Grant date | Mar 12, 2013 |
| Priority date | — |
| Expiry date | Mar 22, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.